Corticosteroid intravitreal implants VS. ranibizumab for the treatment of vitreoretinal disease

Current Opinion in Ophthalmology

Volumn 24, Issue 3, 2013, Pages 248-254

  Comyn, Oliver ^a,b   Lightman, Sue L ^b,c   Hykin, Philip G ^b  

^a NIHR Biomedical Research Centre   (United Kingdom)

^b MOORFIELDS EYE HOSPITAL   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Diabetic Macular Edema; Retinal Vein Occlusion; Uveitis

Indexed keywords

CORTICOSTEROID; DEXAMETHASONE; FLUOCINOLONE ACETONIDE; RANIBIZUMAB;

DIABETIC MACULAR EDEMA; DRUG EFFICACY; HUMAN; INFLAMMATION; INTRAVITREAL IMPLANT; PRIORITY JOURNAL; PSEUDOPHAKIC MACULAR EDEMA; RETINA MACULA EDEMA; RETINA VEIN OCCLUSION; REVIEW; UVEITIS; VITREORETINOPATHY;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; DIABETIC RETINOPATHY; DRUG IMPLANTS; FLUOCINOLONE ACETONIDE; GLUCOCORTICOIDS; HUMANS; MACULAR EDEMA; RETINAL VEIN OCCLUSION; TREATMENT OUTCOME; UVEITIS; VISUAL ACUITY;

EID: 84876291115     PISSN: 10408738     EISSN: 15317021     Source Type: Journal    
DOI: 10.1097/ICU.0b013e32835fab27     Document Type: Review

References (36)

1. Callanan DG, Jaffe GJ, Martin DF, et al. Treatment of posterior uveitis with a fluocinolone acetonide implant: three-year clinical trial results. Arch Ophthalmol 2008; 126:1191-1201.
2. Kane FE, Burdan J, Cutino A, Green KE. Iluvien: a new sustained delivery technology for posterior eye disease. Expert Opin Drug Deliv 2008; 5:1039-1046.
3. Kuppermann BD, Blumenkranz MS, Haller JA, et al. Randomized controlled study of an intravitreous dexamethasone drug delivery system in patients with persistent macular edema. Arch Ophthalmol 2007; 125:309-317.
4. Mitchell P, Bandello F, Schmidt-Erfurth U, et al. The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. Ophthalmology 2011; 118:615-625. This article is the primary report of a randomized controlled trial demonstrating superior benefit for ranibizumab in the treatment of DME compared with laser.
5. Mitchell P. RESTORE extension study group. 2-year Safety and Efficacy Outcome of Ranibizumab 0.5mg in Patients with Visual Impairment Due to Diabetic Macular Edema (DME): an Interim Analysis Of The Restore Extension Study [ARVO Abstract]. Invest Ophthalmol Vis Sci 2012; 53:4667.
6. Elman MJ, Aiello LP, Beck RW, et al. Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology 2010; 117:1064-1077; e1035. The DRCR.net protocol I or LRT trial primary endpoint report. Ranibizumab-treated patients gained nine letters compared to three with laser at 12 months.
7. Elman MJ, Bressler NM, Qin H, et al. Expanded 2-year follow-up of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology 2011; 118:609-614.
8. Nguyen QD, Brown DM, Marcus DM, et al. Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials -RISE and RIDE. Ophthalmology 2012; 119:789-801. The two licensing studies for ranibizumab in DME. Ranibizumab-treated individuals gained 12 letters at 2 years.
9. Pearson PA, Comstock TL, Ip M, et al. Fluocinolone acetonide intravitreal implant for diabetic macular edema: a 3-year multicenter, randomized, controlled clinical trial. Ophthalmology 2011; 118:1580-1587.
10. Campochiaro PA, Brown DM, Pearson A, et al. Long-term benefit of sustained-delivery fluocinolone acetonide vitreous inserts for diabetic macular edema. Ophthalmology 2011; 118:626-635; e622. The primary outcome at 24 months of the FAME study investigating Iluvien in DME. The study continued for a further 12 months with sustained benefit.
11. Campochiaro PA, Brown DM, Pearson A, et al. Sustained delivery fluocinolone acetonide vitreous inserts provide benefit for at least 3 years in patients with diabetic macular edema. Ophthalmology 2012; 119:2125-2132.
12. Haller JA, Kuppermann BD, Blumenkranz MS, et al. Randomized controlled trial of an intravitreous dexamethasone drug delivery system in patients with diabetic macular edema. Arch Ophthalmol 2010; 128:289-296.
13. Boyer DS, Faber D, Gupta S, et al. Dexamethasone intravitreal implant for treatment of diabetic macular edema in vitrectomized patients. Retina 2011; 31:915-923.
14. Brown DM, Campochiaro PA, Singh RP, et al. Ranibizumab for macular edema following central retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmology 2010; 117:1124-1133; e1121. The CRUISE study demonstrating the benefit of ranibizumab in nonischemic CRVO.
15. Campochiaro PA, Brown DM, Awh CC, et al. Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: twelve-month outcomes of a phase III study. Ophthalmology 2011; 118:2041-2049.
16. Heier JS, Campochiaro PA, Yau L, et al. Ranibizumab for macular edema due to retinal vein occlusions: long-term follow-up in the HORIZON trial. Ophthalmology 2012; 119:802-809.
17. Evaluation of grid pattern photocoagulation for macular edema in central vein occlusion. The Central Vein Occlusion Study Group M Report. Ophthalmology 1995; 102:1425-1433.
18. Ip MS, Scott IU, VanVeldhuisen PC, et al. A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with observation to treat vision loss associated with macular edema secondary to central retinal vein occlusion: the Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) study report 5. Arch Ophthalmol 2009; 127:1101-1114.
19. Haller JA, Bandello F, Belfort R Jr., et al. Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion. Ophthalmology 2010; 117:1134-1146; e1133.. The primary endpoint results of the GENEVA studies evaluating Ozurdex in RVO. Patients with BRVO and CRVO were included and randomized to one of two doses of implant or sham.
20. Haller JA, Bandello F, Belfort R Jr., et al. Dexamethasone intravitreal implant in patients with macular edema related to branch or central retinal vein occlusion: twelve-month study results. Ophthalmology 2011; 118:2453-2460.
21. Jain N, Stinnett SS, Jaffe GJ. Prospective study of a fluocinolone acetonide implant for chronic macular edema from central retinal vein occlusion: thirtysix-month results. Ophthalmology 2012; 119:132-137.
22. Campochiaro PA, Heier JS, Feiner L, et al. Ranibizumab for macular edema following branch retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmology 2010; 117:1102-1112; e1101. Primary endpoint of the BRAVO study for ranibizumab in BRVO.
23. Argon laser photocoagulation for macular edema in branch vein occlusion. The Branch Vein Occlusion Study Group. Am J Ophthalmol 1984; 98:271-282.
24. Williams GA, Haller JA, Kuppermann BD, et al. Dexamethasone posteriorsegment drug delivery system in the treatment of macular edema resulting from uveitis or Irvine-Gass syndrome. Am J Ophthalmol 2009; 147:1048-1054; 1054 e1041-e1042.
25. Arevalo JF, Maia M, Garcia-Amaris RA, et al. Intravitreal bevacizumab for refractory pseudophakic cystoid macular edema. Ophthalmology 2009; 116:1481-1487; e1481.
26. Kempen JH, Altaweel MM, Holbrook JT, et al. Randomized comparison of systemic anti-inflammatory therapy versus fluocinolone acetonide implant for intermediate, posterior, and panuveitis: the Multicenter Uveitis Steroid Treatment Trial. Ophthalmology 2011; 118:1916-1926. The MUST trial, suggesting improved visual acuity in individuals treated with Retisert, but narrowly missing statistical significance.
27. Lowder C, Belfort R Jr., Lightman S, et al. Dexamethasone intravitreal implant for noninfectious intermediate or posterior uveitis. Arch Ophthalmol 2011; 129:545-553.
28. Taylor SR, Tomkins-Netzer O, Joshi L, et al. Dexamethasone implant in pediatric uveitis. Ophthalmology 2012; 119:2412-12412; e2412.
29. Acharya NR, Hong KC, Lee SM. Ranibizumab for refractory uveitis-related macular edema. Am J Ophthalmol 2009; 148:303-309; e302.
30. Mavrakanas N, Mendrinos E, Tabatabay C, Pournaras CJ. Intravitreal ranibizumab for choroidal neovascularization secondary to acute multifocal posterior placoid pigment epitheliopathy. Acta Ophthalmol 2010; 88:e54-e55.
31. Shah SP, Hubschman JP, Bourges JL, et al. Limited long-term efficacy of intravitreous anti-VEGF pharmacotherapy in sarcoidosis complicated by peripapillary choroidal neovascular membrane. Acta Ophthalmol 2010; 88:e243-e244.
32. Leung AK, Weisbrod DJ, Schwartz C. Intravitreal ranibizumab in the treatment of choroidal neovascular membrane secondary to punctate inner choroidopathy. Can J Ophthalmol 2010; 45:300-301.
33. Cornish KS, Williams GJ, Gavin MP, Imrie FR. Visual and optical coherence tomography outcomes of intravitreal bevacizumab and ranibizumab in inflammatory choroidal neovascularization secondary to punctate inner choroidopathy. Eur J Ophthalmol 2011; 21:440-445.
34. Lyall DA, Hutchison BM, Gaskell A, Varikkara M. Intravitreal ranibizumab in the treatment of choroidal neovascularisation secondary to ocular toxocariasis in a 13-year-old boy. Eye (Lond) 2010; 24:1730-1731.
35. Rouvas A, Petrou P, Douvali M, et al. Intravitreal ranibizumab for the treatment of inflammatory choroidal neovascularization. Retina 2011; 31:871-879.
36. Troutbeck R, Bunting R, van Heerdon A, et al. Ranibizumab therapy for choroidal neovascularization secondary to nonage-related macular degeneration causes. Clin Exper Ophthalmol 2012; 40:67-72.